title: Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
abstract: Acute renal failure (ARF) is a common life-threatening complication after myeloablative allogeneic hematopoietic cell transplantation (HCT). Nonmyeloablative HCT aims to eradicate the malignancy with graft-versus-tumor effect, rather than with high doses of chemoradiotherapy. It may be anticipated that a lower risk of ARF exists in nonmyeloablative HCT as a result of the milder preconditioning regimen. However, the patients who receive the nonmyeloablative HCT are older individuals who are not eligible for the more toxic allogeneic myeloablative procedure. The goal of this study was to evaluate ARF in a large group of patients who received nonmyeloablative HCT. This cohort study enrolled patients who were undergoing nonmyeloablative HCT at four major centers from 1998 to 2001. Conditioning therapy involved total body irradiation 2 Gy +/- fludarabine 30 mg/m2. Posttransplantation immunosuppression consisted of cyclosporine or tacrolimus and mycophenolate mofetil. ARF was classified into four grades, similar to previous studies in the literature. Collectively, 253 patients were recruited into this study. ARF (>50% decrease in GFR) occurred in 40.4% of patients over a 3-mo period, with 4.4% of patients requiring dialysis. The overall mortality in the study population was 34% at 1 yr. The mortality increased with worsening grade of ARF. The combined need for dialysis and artificial ventilation was associated with a mortality exceeding 80%. Although the number of patients who develop ARF is significant, the risk of developing ARF that requires dialysis after nonmyeloablative HCT is infrequent despite the older age of the patients. The data are also suggestive that ARF may contribute to mortality after nonmyeloablative HCT.
authors.affiliation: Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado, USA.
authors.forename: Chirag R
authors.initials: CR
authors.lastname: Parikh
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Sandmaier
authors.forename: Rainer F
authors.initials: RF
authors.lastname: Storb
authors.forename: Karl G
authors.initials: KG
authors.lastname: Blume
authors.forename: Firoozeh
authors.initials: F
authors.lastname: Sahebi
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: Michael B
authors.initials: MB
authors.lastname: Maris
authors.forename: Yago
authors.initials: Y
authors.lastname: Nieto
authors.forename: Charles L
authors.initials: CL
authors.lastname: Edelstein
authors.forename: Robert W
authors.initials: RW
authors.lastname: Schrier
authors.forename: Peter
authors.initials: P
authors.lastname: McSweeney
mesh_terms: D058186:Acute Kidney Injury / Q000473:pathology*; D000328:Adult; D000368:Aged; D001521:Behavior Therapy; D015331:Cohort Studies; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005919:Glomerular Filtration Rate; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D014740:Vidarabine; D009173:Mycophenolic Acid; C024352:fludarabine; D016559:Tacrolimus